- NurExone Biologic (NRX) received a notice from the United States Patent and Trademark Office
- The patent protects NurExone’s Exo-PTEN technology, and its drug composition as well as methods for non-invasive intranasal administration of exosome-based treatment for patients with traumatic spinal cord injuries
- The patent was born from collaboration between the Technion (the Israel Institute of Technology) and Tel Aviv University
- NurExone Biologic Inc. (NRX) opened trading at $0.32 per share
NurExone Biologic (NRX) received a notice from the United States Patent and Trademark Office.
The patent protects NurExone’s Exo-PTEN technology, and its drug composition as well as methods for non-invasive intranasal administration of exosome-based treatment for patients with traumatic spinal cord injuries.
The patent was born from collaboration between the Technion (the Israel Institute of Technology) and Tel Aviv University. NurExone has an exclusive license on the granted patent.
To strengthen the Exo-PTEN technology platform protection the company intends to file a child ‘continuation’ patent application to include additional claims on the method of treatment and indication of the Exo-PTEN platform.
One of the inventors, Dr. Nisim Perets is currently leading the technology transfer activities in NurExone’s research and development team.
“The latest patent expands our intellectual property portfolio and enables us to be the exclusive provider of this unique exosome-based therapy that is designed to treat acute spinal cord injuries,” said Dr. Lior Shaltiel, CEO of NurExone.
Counterparts of the U.S. patent are being examined in different countries around the world. The patent has been granted for the period of 20 years from filing date until March 27, 2039.
NurExone Biologic Inc. is a pharmaceutical company developing a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries.
NurExone Biologic Inc. (NRX) opened trading at $0.32 per share.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.